Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Therapeutical antibodies > cantuzumab

cantuzumab

Thursday 12 April 2012

Cantuzumab is a monoclonal antibody designed for the treatment of cancers.

It is typically linked to one of several cytotoxic agents, yielding:

- Cantuzumab mertansine
- Cantuzumab ravtansine

Cantuzumab mertansine

Cantuzumab mertansine is a humanized monoclonal antibody used to treat colorectal cancer and other types of cancer. It is linked to a cytotoxic agent, mertansine. Three phase I clinical studies had reported results by 2003.

Cantuzumab mertansine (SB-408075; huC242-DM1) is a conjugate of the maytansinoid drug DM1 to the antibody huC242, which targets CanAg antigen.

In some studies, cantuzumab mertansine was considered safe and tolerable, but transaminitis precluded tolerance of higher doses.

Based on those studies, it was suggested that treatment at intervals of the half-life of the intact immunoconjugate may allow a higher dose density.

Cantuzumab ravtansine

Cantuzumab ravtansine is a humanized monoclonal antibody designed for the treatment of cancers. The antibody cantuzumab is linked to a cytotoxic agent, ravtansine.

References

- Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cancer Chemother Pharmacol. 2008 Oct;62(5):911-9. PMID: #18301896#